EMA Recommends Granting a Conditional Marketing Authorisation for Rucaparib

2018-03-27 03:31:00

It is recommended in previously treated platinum-sensitive, relapsed or progressive BRCA mutated high-grade epithelial ovarian cancer


Oncology Breast CNS Chemotherapy Endocrine GI GU Geriatric Gynecologic GYN-OB Head and Neck Haematology Immunotherapy Lung Melanoma Skin NET Paediatric Pathology Sarcoma Surgery Targeted Therapy Translational
  • Save
0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply